Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects

Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects

Background: The influenza B virus has two lineages; Yamagata and Victoria. The two lineages are antigenically distinct and it is difficult to expect cross-protection between the lineages. Actually, the mismatch between circulating influenza B viruses and vaccine strains has been occurred frequently....

Full description

Bibliographic Details
Main Authors: Won Suk Choi, Ji Yun Noh, Joon Young Song, Hee Jin Cheong, Seong-Heon Wie, Jin Soo Lee, Jacob Lee, Shin-Woo Kim, Hye Won Jeong, Sook-In Jung, Yeon-Sook Kim, Heung Jeong Woo, Kyung Ho Kim, Hun Kim, Woo Joo Kim
Format: Article
Language:English
Published: Taylor & Francis Group 2017-07-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
cell culture techniques
clinical trial
human
inactivated
influenza b virus
influenza vaccine
vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2017.1297351

Internet

http://dx.doi.org/10.1080/21645515.2017.1297351

Similar Items